We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mindray to Acquire 75% Stake in DiaSys

By LabMedica International staff writers
Posted on 04 Aug 2023
Print article
Image: Mindray has agreed to acquire 75% equity interest in DiaSys (Photo courtesy of Mindray)
Image: Mindray has agreed to acquire 75% equity interest in DiaSys (Photo courtesy of Mindray)

Mindray (Shenzhen, China) has agreed to acquire a 75% equity interest in DiaSys Diagnostic Systems GmbH (Holzheim, Germany) through its Dutch subsidiary for an all-cash preliminary purchase price of approximately EUR 115 million with the final amount to be determined as of closing. The agreement is slated to be finalized later this year, pending regulatory approvals and the granting of regulatory approvals. Upon finalizing the transaction, Mindray will hold a 75% stake in DiaSys and consolidate DiaSys and its subsidiaries. DiaSys's wide range of clinical chemistry systems, manufacturing capabilities for controls and calibrators, and a global network of manufacturing and distribution sites synergize fully complement Mindray's extensive hematology and immunoassays product range, creating a plethora of market opportunities.

Recognized globally, DiaSys has over 30 years of experience in the in-vitro diagnostics (IVD) field with production facilities spread across Europe, APAC, and Latin America. Mindray intends to utilize DiaSys's international team of professionals and global supply platforms to expedite the construction of overseas supply chains, aiming for further expansion into global medium to large volume customer segments and delivering more timely and comprehensive professional services to clients. Moreover, DiaSys's vast experience in clinical chemistry is anticipated to bring synergistic value to Mindray's IVD business. DiaSys’s expertise in developing and producing IVD controls and calibrators will complement Mindray’s IVD product line and enhance its system performance.

“We are very pleased to see this collaboration come to fruition, as Mindray’s and DiaSys’ businesses strongly complement each other,” said Wu Hao, President of Mindray. “Through this acquisition, Mindray will effectively improve its overseas supply chain platform and support the penetration of our IVD business in the medium to large customer segments. We look forward to both parties jointly realizing synergies and creating greater value for our customers.”

“DiaSys with its comprehensive range of products and global manufacturing footprints, and Mindray with its total IVD solutions and worldwide network, are ideal partners for lifting synergies in the IVD field,” added Dr. Günther Gorka, DiaSys’s Founder. “The individual strengths of both partners will support each other and help for a common and sustainable success in all regions of the world.”

Related Links:
Mindray
DiaSys Diagnostic Systems

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.